Is there any therapeutic value for the use of histone deacetylase inhibitors for chronic pain?
详细信息 查看全文
- 作者：Wei Wanga ; weiwang@fmmu.edu.cn" class="auth_mail" title="E-mail the corresponding author ; Shan-shan Cuib ; 630170543@qq.com" class="auth_mail" title="E-mail the corresponding author ; Rui Lua ; 18291855734@163.com" class="auth_mail" title="E-mail the corresponding author ; Hui Zhanga ; zhanghuifmmua@yahoo.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：BDNF ; brain derived neurotropic factor ; CCI ; chronic constriction injury ; CFA ; complete Freund&rsquo ; s adjuvant ; CNS ; central nervous system ; GAD ; glutamic acid decarboxylase ; GLT-1 ; glutamate transporter-1 ; HDACs ; histone deacetylases ; HDACI ; histone deacetylase inhibitor ; HATs ; histone acetyltransferases ; LPS ; lipopolysaccharide ; MORs ; μ-opioid receptors ; NRM ; nucleus raphe magnus ; NRSE ; neuron-restrictive silencer element ; PSL ; partial sciatic nerve ligation ; SAHA ; suberoylanilide hydroxamic
- 刊名：Brain Research Bulletin
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：125
- 期：Complete
- 页码：44-52
- 全文大小：864 K
文摘
- •
Histone deacetylases (HDAC) are dynamically changed in pain development.
- •
HDAC inhibitors have been demonstrated to have therapeutic effects in pain.
- •
HDAC inhibitors have limitations including non-specificity on targeted genes.